In our November issue:
FEATURES
Cover Story
Pharm Exec’s 2015 Pipeline Report
Josh Baxt
In the next few years, cancer immunotherapies are likely to enter the pantheon of big winners. There’s a buzz around a cure for hepatitis C virus, and exciting drugs for heart failure and cholesterolemia are coming into play. Stem cells are also making real forays into late-stage trials. But is pharma ready to raise its game and cut a deal with all those "prove it to me" payers? |
Sales & Marketing
Sales Reps and the New Commercial Organization
Ian Wilcox
Structural transformations in the life sciences industry have put the traditional sales role under increasing scrutiny, with the most prominent change being a drastic reduction in field force deployments in the US and Europe. This, argues Hay Group's Ian Wilcox, is where opportunity lies. |
Executive Interview
Dane in America: Novo Nordisk’s Jesper Hoiland
William Looney
Novo Nordisk’s Senior Vice President for North America, Jesper Hoiland, talks to about his first year on the job at the company’s regional headquarters in Princeton, including an unsettling initial encounter with the growing clout of pharmacy benefit manager (PBM) medicines gatekeepers; looming price wars; and implementing what he sees as the three essential contributors to CEO leadership success. |
From the Editor
Pharma Science: It’s Hard
William Looney
It’s a good time to be a patient. The larger question is whether the times are as good for the industry that accounts disproportionately for the task of rendering basic science into therapeutically effective medicines, able to perform consistently across a target patient population. The truth is there are some real tears in the patchwork gauze that binds a new entry to the commercial market. |
 |
ALSO IN THIS ISSUE
Outrage Grows Over Drug Pricing
Jill Wechsler
It may be time for pharmaceutical executives to devise a new rationale for drug pricing other than the need for high returns to support research and innovation.
The European Medicines Agency — a Pioneer Permanently at Bay
Reflector
Agency's plan for reporting clinical trial data has sparked strong reactions from health campaigners, industry, and patients. |
|
 |
|
